Bulk Acoustic Wave Sensor Technology In Veterinary Medicine
Advancing Patient Health with TRUFORMA™, Zomedica’s First Point-of-Care Diagnostic Platform
Veterinarians are most familiar with point-of-care (POC) immunoassays used to screen dogs for vector-borne diseases, such as heartworm, Lyme disease, ehrlichiosis, and anaplasmosis, and cats for retroviral diseases, such as feline leukemia virus and feline immunodeficiency virus. Veterinarians may be less aware of their reliance on immunoassays in the detection of biomarkers associated with non-infectious diseases, including endocrine, gastrointestinal, allergic, and metabolic disorders. Although point-of-care immunoassays are reliable for the quantitative screening of dogs and cats for several infectious diseases, performance of POC immunoassays for the quantification of other biomarkers, such as hormones, has been questionable at best. Consequently, immunoassay testing for the majority of infectious and non-infectious diseases must be performed in a reference laboratory to ensure that such conditions are accurately diagnosed. This is due to the high complexity and costs associated with current immunoassay testing methodologies and equipment necessary to provide a “gold standard” of diagnostic accuracy.
Zomedica challenges this paradigm with TRUFORMA™, a biosensor platform, designed to provide accurate thyroid and adrenal testing at the point-of-care. TRUFORMA™ is a table-top instrument that will use disposable assay cartridges to test a range of samples including whole blood, serum, and plasma. The platform uses differentiated Bulk Acoustic Wave (BAW) sensor technology to provide a non-optical and fluorescence-free detection system for use at the point-of-care—enhancing the standard of care provided by veterinarians and their teams to our companion animals.